The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 15, 2026
Filed:
Dec. 23, 2022
Applicant:
Pelemed Co., Ltd., Seoul, KR;
Inventors:
Soo Yeon Jang, Seoul, KR;
Myung Jin Kim, Seoul, KR;
Jin Hee Park, Seoul, KR;
So Deok Lee, Gwangju, KR;
Su Jin Oh, Seoul, KR;
Eun Ji Lee, Seoul, KR;
Yong Chul Kim, Gwangju, KR;
Woo Chan Kim, Daejeon, KR;
Je Heon Lee, Daejeon, KR;
Assignee:
Pelemed Co., Ltd., Gwangju, KR;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 403/14 (2006.01); A61P 35/00 (2006.01); C07D 471/18 (2006.01); C07D 487/10 (2006.01);
U.S. Cl.
CPC ...
C07D 403/14 (2013.01); A61P 35/00 (2018.01); C07D 471/18 (2013.01); C07D 487/10 (2013.01);
Abstract
The present invention relates to novel indirubin derivatives having heterobicyclic moieties, and use thereof as fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinase inhibitors. The compound of the present invention effectively inhibits the activity of FLT3 and RET kinases, and thus may be useful for preventing or treating mutant FLT3 and mutant RET-related diseases, particularly acute myeloid leukemia.